In search of an effective treatment for recurrent mesangiocapillary glomerulonephritis in the renal allograft

Michael Cai, Ian Simpson, William Mulley

Research output: Contribution to journalArticleOther

2 Citations (Scopus)

Abstract

In patients with end-stage kidney disease (ESKD) secondary to mesangiocapillary glomerulonephritis (MCGN), recurrent disease post transplantation is a common cause of graft loss. We report a case of a 33-year-old female with ESKD due to idiopathic MCGN who developed recurrent disease in two consecutive renal allografts. Recurrent disease was diagnosed two months after receiving her primary transplant from a live related donor. Oral cyclophosphamide was initiated but discontinued after 10 months due to cystitis. This was followed by rapid deterioration in her renal function. Despite salvage therapy with rituximab, the graft was lost 2 years post transplantation. After 7 years on haemodialysis, the patient received a second graft from a deceased donor. Recurrent MCGN was once again diagnosed one year post transplantation. She was treated with plasma exchange and rituximab. Despite ongoing nephrotic range proteinuria, her graft function remained stable 2 years post transplantation. The optimal therapy for recurrent MCGN is unknown at this stage. It is hoped that a better understanding of its pathogenesis will enable the development of more effective and targeted therapies.
Original languageEnglish
Pages (from-to)6 - 9
Number of pages4
JournalNephrology
Volume19 sup 1
DOIs
Publication statusPublished - 2014

Cite this

@article{13207f1ccba3482a9dfe39d11094ed70,
title = "In search of an effective treatment for recurrent mesangiocapillary glomerulonephritis in the renal allograft",
abstract = "In patients with end-stage kidney disease (ESKD) secondary to mesangiocapillary glomerulonephritis (MCGN), recurrent disease post transplantation is a common cause of graft loss. We report a case of a 33-year-old female with ESKD due to idiopathic MCGN who developed recurrent disease in two consecutive renal allografts. Recurrent disease was diagnosed two months after receiving her primary transplant from a live related donor. Oral cyclophosphamide was initiated but discontinued after 10 months due to cystitis. This was followed by rapid deterioration in her renal function. Despite salvage therapy with rituximab, the graft was lost 2 years post transplantation. After 7 years on haemodialysis, the patient received a second graft from a deceased donor. Recurrent MCGN was once again diagnosed one year post transplantation. She was treated with plasma exchange and rituximab. Despite ongoing nephrotic range proteinuria, her graft function remained stable 2 years post transplantation. The optimal therapy for recurrent MCGN is unknown at this stage. It is hoped that a better understanding of its pathogenesis will enable the development of more effective and targeted therapies.",
author = "Michael Cai and Ian Simpson and William Mulley",
year = "2014",
doi = "10.1111/nep.12191",
language = "English",
volume = "19 sup 1",
pages = "6 -- 9",
journal = "Nephrology",
issn = "1320-5358",
publisher = "Wiley-Blackwell",

}

In search of an effective treatment for recurrent mesangiocapillary glomerulonephritis in the renal allograft. / Cai, Michael; Simpson, Ian; Mulley, William.

In: Nephrology, Vol. 19 sup 1, 2014, p. 6 - 9.

Research output: Contribution to journalArticleOther

TY - JOUR

T1 - In search of an effective treatment for recurrent mesangiocapillary glomerulonephritis in the renal allograft

AU - Cai, Michael

AU - Simpson, Ian

AU - Mulley, William

PY - 2014

Y1 - 2014

N2 - In patients with end-stage kidney disease (ESKD) secondary to mesangiocapillary glomerulonephritis (MCGN), recurrent disease post transplantation is a common cause of graft loss. We report a case of a 33-year-old female with ESKD due to idiopathic MCGN who developed recurrent disease in two consecutive renal allografts. Recurrent disease was diagnosed two months after receiving her primary transplant from a live related donor. Oral cyclophosphamide was initiated but discontinued after 10 months due to cystitis. This was followed by rapid deterioration in her renal function. Despite salvage therapy with rituximab, the graft was lost 2 years post transplantation. After 7 years on haemodialysis, the patient received a second graft from a deceased donor. Recurrent MCGN was once again diagnosed one year post transplantation. She was treated with plasma exchange and rituximab. Despite ongoing nephrotic range proteinuria, her graft function remained stable 2 years post transplantation. The optimal therapy for recurrent MCGN is unknown at this stage. It is hoped that a better understanding of its pathogenesis will enable the development of more effective and targeted therapies.

AB - In patients with end-stage kidney disease (ESKD) secondary to mesangiocapillary glomerulonephritis (MCGN), recurrent disease post transplantation is a common cause of graft loss. We report a case of a 33-year-old female with ESKD due to idiopathic MCGN who developed recurrent disease in two consecutive renal allografts. Recurrent disease was diagnosed two months after receiving her primary transplant from a live related donor. Oral cyclophosphamide was initiated but discontinued after 10 months due to cystitis. This was followed by rapid deterioration in her renal function. Despite salvage therapy with rituximab, the graft was lost 2 years post transplantation. After 7 years on haemodialysis, the patient received a second graft from a deceased donor. Recurrent MCGN was once again diagnosed one year post transplantation. She was treated with plasma exchange and rituximab. Despite ongoing nephrotic range proteinuria, her graft function remained stable 2 years post transplantation. The optimal therapy for recurrent MCGN is unknown at this stage. It is hoped that a better understanding of its pathogenesis will enable the development of more effective and targeted therapies.

UR - http://onlinelibrary.wiley.com/doi/10.1111/nep.12191/epdf

U2 - 10.1111/nep.12191

DO - 10.1111/nep.12191

M3 - Article

VL - 19 sup 1

SP - 6

EP - 9

JO - Nephrology

JF - Nephrology

SN - 1320-5358

ER -